Medicinal and Organic Chemistry Expert: Antibacterials and Antiparasitics

Technical Consultant #2050


  • Medicinal and organic chemistry: program review, SAR analysis, new targets, direct programs at CROs.
  • Therapeutic areas: Antibacterials, antiparasitics, steroids, natural products, estrogen receptor, diabetes, obesity, thrombosis, and animal health.
  • Evaluation of drug discovery programs and potential products as part of investor due diligence.
  • Synthetic route design and troubleshooting.
  • Structure determination of unknown reaction products and novel compounds.
  • Radiolabeled pharmaceuticals - compound design and synthetic strategy.
  • Review of legal documents for scientific accuracy.
  • Evaluation of grant proposals.

Expert Witness Experience

  • Subject Matter Expert in organic chemistry, synthetic chemistry, and organic reaction mechanisms.
  • Patent coverage evaluation - identify potential gaps ("patent busting").


Undisclosed Company, Vice President and Chemistry Contractor, Present

  • Direct the chemistry aspects of the Company's research and development programs.
  • Provided drug discovery consulting services to the Company.

Undisclosed Company, Senior Consultant and Founder, Present

  • Served on review panels for NIH (National Institute of Health); reviewed SBIR (Small Business Innovation Research) /STTR (Small Business Technology Transfer) grant applications.
  • Served on review panels for DOD (Department of Defense) organized by SRA International (Society of Research Administrators); reviewed grant applications.
  • Evaluations of research programs and potential development compounds for a venture capital firms.
  • Served as drug discovery consultant and part time VP of Chemistry for RiboNova.

Merck & Co., Inc., Rahway, NJ, Principal Scientist, 1985 - 2013

Distinguished Senior Investigator, 2007
Senior Investigator, 1999
Associate Director, 1994
Research Fellow, 1989
Senior Research Chemist, 1985

  • Led the chemistry team that discovered MK-7655, a beta-lactamase inhibitor that is currently in Phase II clinical trials.
  • Served as chemistry representative on the Early Development Team (EDT) for MK-8712.
  • Led the chemistry group (10 chemists) that discovered two carbapenem antibiotic preclinical candidates for the treatment of MRSA infections. One, L-786,392, advanced to a Phase I multi-dose clinical trial.
  • Directed external groups (up to 25 chemists) on 4 programs at CROs (WuXi (China) and AMRI (Singapore).
  • Participated in outsourcing and licensing activities including visits to Shanghai, China and Gotembe, Japan.
  • Member of the Process Chemistry Scientific Advisory Committee (SAC), a team of senior chemists that served as internal consultants and reviewed synthetic routes for development compounds and suggested improvements that increased efficiency and reduced costs.
  • Member of the Late Stage Functionalization group, a team of experienced synthetic chemists that was formed to apply the latest synthetic methodology to complex drug molecules.
  • Member of the Stereochemical Assignment Task Force, a group of senior Merck scientists that was assigned to solve stereochemical problems.
  • Key contributor to the discovery of ER-alpha "super antagonists" active against Tamoxifen-resistant tumors and the discovery of a novel anti-hypertensive agent.
  • Discovered a series of promising next-generation avermectins for parasitic infections in dogs.
  • Developed an in vitro assay using brine shrimp as a useful surrogate for antiparasitic activity.
  • Worked with patent attorneys to ensure intellectual property protection; drafted the claim structure for some patents.
  • Developed method for isotopic labeling of paraherquamide, an anti-parasitic oxindole alkaloid.

Columbia University, New York, NY, Postdoctoral Research Scientist, 1984 -1985

  • Postdoctoral research in natural products chemistry and organic synthesis with Professor Koji Nakanishi.
  • Investigated the synthesis of steroidal marine natural products with shark repellent activity.
  • Prepared steroids, including a C-14 labeled steroid, for studies on cholesterol metabolism.
  • Isolated and purified brevetoxins from cultures brevetoxins from cultures of K. Brevis using established procedures.

Honors & Publications


  • Mandarin Chinese (beginner level)

Academic and Professional Affiliations

  • American Chemical Society - member, Organic and Medicinal Chemistry Divisions; served on two ACS award committees for 3 years each.
  • New York Academy of Sciences - member
  • Merck Polytechnic Institute courses: "Managing Across Cultures" and "Partnering Excellence"
  • Rutgers Center for Management Development - mini-MBA Biopharma Innovation (six-day program)
  • Partner Communications Course: "Executive Presentations Program"
  • Leadership Courses: "Innovate Like Edison" & "Creativity and Innovation Leadership"
  • Merck Research Laboratories Leadership Development Program


  • Postdoctoral Fellowship, National Institutes of Health
  • Graduate Fellowship, Whitaker Health Sciences Fund (M.I.T.)
  • Graduate Fellowship, National Science Foundation

Publications and Patents

  • Author and Co-Author of numerous publications in peer reviewed medical journals, science journals and other literature.
  • National meetings, lectures, and symposia
  • 19 U.S. patents


  • Ph.D. Organic Chemistry, Massachusetts Institute Of Technology, Cambridge, MA
  • B.S. Chemistry, University Of Virginia, Charlottesville, VA
Save Resume #2050
to Contact Form?

You must first click "Yes" to save this resume

Submit Request

You have no Saved Resumes

Add resumes within our various Ares of Expertise by clicking "Add Resume(s)" below.

Add Resume(s)